Zydus Launches India’s First Indigenous Aflibercept Biosimilar ANYRA™ for Eye Care

Zydus Lifesciences has introduced ANYRA™, India’s first locally developed biosimilar of Aflibercept 2 mg, aimed at improving treatment options for serious eye diseases. The company has also entered into an agreement with Regeneron Pharmaceuticals, Inc. and Bayer as part of this development.

Treatment Uses and Patient Need

ANYRA™ is used to treat several vision-threatening conditions. These include wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and myopic choroidal neovascularization.
India has a very large diabetic population, with millions already affected by diabetic retinopathy and related complications. Other retinal diseases such as wet AMD and retinal vein occlusions also impact millions of patients, creating a strong need for timely and affordable treatment to prevent permanent vision loss.

Importance of Affordable Biologics

Chronic retinal diseases usually require repeated eye injections over long periods, which can make treatment expensive and difficult to continue. Increasing access to affordable biologic medicines like ANYRA™ can improve treatment adherence, reduce avoidable blindness, and lower the long-term healthcare burden.

Zydus’ Biologics Capabilities

Zydus has built one of India’s largest biosimilar portfolios, with more than 13 biosimilars and complex biologic products developed and manufactured within the country. The company has full capabilities across research, clinical trials, manufacturing, and regulatory approvals, supporting innovation in advanced therapies.

Zydus Lifesciences Share Price Movement

Zydus Lifesciences share price (NSE: ZYDUSLIFE) was trading at ₹913.15 on 19 February at 10:52 am IST, up ₹3.10 or 0.34% for the day. The stock opened at ₹919.75 and touched an intraday high of ₹919.75 and a low of ₹911.40. The company’s market capitalisation stands at around ₹91.85 thousand crore, with a price-to-earnings (P/E) ratio of 18.60. Its 52-week high is ₹1,059.05, while the 52-week low is ₹795.00. The stock offers a dividend yield of 1.21%, with a quarterly dividend amount of ₹2.76.

Also Read: Best PSU Stocks in India in February 2026!

Conclusion

The launch of ANYRA™ marks a significant step toward accessible and affordable retinal care in India. By combining scientific innovation with local manufacturing, Zydus aims to expand treatment reach and protect vision for millions of patients in need.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.